Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Website: aravive.com



Growth: Bad revenue growth rate -40.0%, there is slowdown compared to average historical growth rates 50.1%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -866.7%. On average the margin is decreasing steadily. Gross margin is low, -216.8%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.10 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -592.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.0% higher than minimum and 99.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -39.5x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ARAV
Share price, USD:  (0.0%)0.0401
year average price 0.4863  


year start price 1.4200 2023-04-29

max close price 1.8000 2023-06-02

min close price 0.0401 2024-01-26

current price 0.0401 2024-04-27
Common stocks: 75 739 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  -40.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  50.1%
Historical growth of EBITDA:  0.0%
EV / Sales: -0.3x
Margin (EBITDA LTM / Revenue): -866.7%
Fundamental value created in LTM:
Market Cap ($m): 3
Net Debt ($m): -5
EV (Enterprise Value): -2
Price to Book: 1.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-10-13Zacks Investment Research

Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?

2023-08-21Zacks Investment Research

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

2023-08-03InvestorPlace

Why Is Aravive (ARAV) Stock Down 58% Today?

2023-05-25GlobeNewsWire

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

2023-04-17Zacks Investment Research

What Makes Aravive (ARAV) a New Buy Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ARAV ARAV ARAV ARAV ARAV
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-09 2023-08-21 2023-05-10 2023-03-15 2022-11-10
acceptedDate 2023-11-09 16:05:43 2023-08-21 16:05:30 2023-05-10 16:07:10 2023-03-15 07:05:45 2022-11-10 07:15:37
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
revenue 3M 1M 1M 1M 5M
costOfRevenue 9M 11M 0 0 0
grossProfit -6M -10M 1M 1M 5M
grossProfitRatio -2.168 -7.469 1.000 1.000 1.000
researchAndDevelopmentExpenses 9M 11M 16M 18M 19M
generalAndAdministrativeExpenses 3M 3M 3M 3M 3M
sellingAndMarketingExpenses 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3M 3M 3M 3M 3M
otherExpenses 700 000 650 000 697 000 -9M 0
operatingExpenses 12M 14M 19M 21M 22M
costAndExpenses 12M 14M 19M 21M 22M
interestIncome 209 000 352 000 467 000 433 000 147 000
interestExpense 0 0 33M -220 000 147 000
depreciationAndAmortization 222 000 221 000 215 000 222 000 221 000
ebitda -38M -42M 16M -20M -16M
ebitdaratio -13.760 -32.933 10.402 -13.476 -3.294
operatingIncome -9M -13M 15M -20M -17M
operatingIncomeRatio -3.234 -9.879 10.258 -13.476 -3.339
totalOtherIncomeExpensesNet 30M 30M -65M -9M 885 000
incomeBeforeTax 21M 18M -50M -29M -16M
incomeBeforeTaxRatio 7.702 14.135 -33.505 -19.759 -3.160
incomeTaxExpense -29M -30M 32M 9M -1M
netIncome 21M 18M -82M -38M -15M
netIncomeRatio 7.702 14.135 -54.996 -26.041 -2.952
eps 0.280 0.240 -1.080 -0.610 -0.480
epsdiluted 0.280 -0.120 -1.080 -0.610 -0.480
weightedAverageShsOut 76M 100M 76M 63M 31M
weightedAverageShsOutDil 76M 100M 76M 63M 31M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ARAV ARAV ARAV ARAV ARAV
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-09 2023-08-21 2023-05-10 2023-03-15 2022-11-10
acceptedDate 2023-11-09 16:05:43 2023-08-21 16:05:30 2023-05-10 16:07:10 2023-03-15 07:05:45 2022-11-10 07:15:37
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 9M 18M 36M 54M 28M
shortTermInvestments 0 0 0 0 0
cashAndShortTermInvestments 9M 18M 36M 54M 28M
netReceivables 0 0 0 0 6M
inventory 0 0 0 0 0
otherCurrentAssets 1M 4M 3M 4M 4M
totalCurrentAssets 10M 22M 39M 56M 38M
propertyPlantEquipmentNet 1M 1M 2M 1M 2M
goodwill 0 0 0 0 0
intangibleAssets 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0
longTermInvestments 0 0 0 0 0
taxAssets 0 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 5M 2M
totalNonCurrentAssets 3M 4M 4M 6M 4M
otherAssets 0 0 0 0 0
totalAssets 13M 26M 43M 62M 42M
accountPayables 5M 4M 10M 9M 9M
shortTermDebt 2M 2M 2M 2M 2M
taxPayables 0 0 0 0 0
deferredRevenue 0 3M 4M 5M 5M
otherCurrentLiabilities 2M 6M 5M 5M 7M
totalCurrentLiabilities 10M 14M 20M 21M 24M
longTermDebt 306 000 821 000 1M 4M 2M
deferredRevenueNonCurrent 0 16 000 28 000 621 000 1M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0
otherNonCurrentLiabilities 1M 30M 60M 26M -13M
totalNonCurrentLiabilities 2M 31M 61M 31M 3M
otherLiabilities 0 0 0 0 0
capitalLeaseObligations 2M 3M 4M 4M 5M
totalLiabilities 11M 46M 82M 51M 27M
preferredStock 0 0 0 0 0
commonStock 7000.000 6000.000 6000.000 6000.000 3000.000
retainedEarnings -627M -648M -666M -616M -587M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0
othertotalStockholdersEquity 629M 628M 627M 627M 602M
totalStockholdersEquity 2M -20M -39M 11M 15M
totalEquity 2M -20M -39M 11M 15M
totalLiabilitiesAndStockholdersEquity 13M 26M 43M 62M 42M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 13M 26M 43M 62M 42M
totalInvestments 0 0 0 0 0
totalDebt 2M 3M 4M 6M 5M
netDebt -6M -15M -32M -47M -23M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ARAV ARAV ARAV ARAV ARAV
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-09 2023-08-21 2023-05-10 2023-03-15 2022-11-10
acceptedDate 2023-11-09 16:05:43 2023-08-21 16:05:30 2023-05-10 16:07:10 2023-03-15 07:05:45 2022-11-10 07:15:37
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3
netIncome 21M 18M -50M -29M -16M
depreciationAndAmortization 222 000 221 000 215 000 222 000 221 000
deferredIncomeTax -78M -80M 0 0 0
stockBasedCompensation 292 000 761 000 688 000 576 000 639 000
changeInWorkingCapital -2M -7M -2M 3M -4M
accountsReceivables 0 0 0 0 0
inventory 0 0 0 0 0
accountsPayables 2M -6M 1M -56 000 4M
otherWorkingCapital -4M -1M -3M 3M -8M
otherNonCashItems 49M 50M 33M 11M 0
netCashProvidedByOperatingActivities -10M -18M -18M -14M -19M
investmentsInPropertyPlantAndEquipment 0 0 0 -11 000 0
acquisitionsNet 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 -11 000 0
debtRepayment 0 0 0 0 0
commonStockIssued 25 000 25 000 0 40M 3 185M
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites -25 000 0 0 0 -3 185M
netCashUsedProvidedByFinancingActivities 25 000 25 000 0 40M 3 185M
effectOfForexChangesOnCash 0 0 0 0 0
netChangeInCash -10M -18M -18M 26M -19M
cashAtEndOfPeriod 11M 21M 38M 56M 30M
cashAtBeginningOfPeriod 21M 38M 56M 30M 49M
operatingCashFlow -10M -18M -18M -14M -19M
capitalExpenditure 0 0 0 -11 000 0
freeCashFlow -10M -18M -18M -14M -19M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-01-17 21:09 ET
Aravive, Inc. to Delist from The Nasdaq Stock Market
2023-08-02 20:01 ET
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
2023-07-28 11:05 ET
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
2023-07-14 11:05 ET
Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
2023-06-13 20:05 ET
Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
2023-06-05 20:05 ET
Aravive To Participate in the Jefferies Global Healthcare Conference
2023-05-25 21:00 ET
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
2023-05-16 11:05 ET
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
2023-05-10 20:05 ET
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
2023-05-08 11:05 ET
Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
2023-04-26 21:00 ET
Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
2023-04-11 11:05 ET
Aravive Appoints Carolina Petrini as Chief Commercial Officer
2023-03-15 11:00 ET
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
2023-02-28 21:05 ET
Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer
2023-02-13 22:00 ET
Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
2023-01-04 12:05 ET
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
2022-11-29 12:00 ET
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
2022-11-21 12:00 ET
Aravive To Participate in Piper’s 34th Annual Healthcare Conference
2022-11-16 12:00 ET
Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement
2022-11-10 12:00 ET
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
2022-10-25 11:30 ET
Aravive Announces Approximately $41.5 Million Private Placement Financing
2022-10-10 20:05 ET
Aravive Receives Third Development Milestone from 3D Medicines
2022-09-26 12:00 ET
Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
2022-09-06 20:05 ET
Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
2022-08-11 11:00 ET
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
2022-07-05 13:07 ET
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
2022-06-03 11:00 ET
Aravive Appoints Rudy Howard as Chief Financial Officer
2022-05-26 21:11 ET
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
2022-05-17 11:00 ET
Aravive to Participate in H.C. Wainwright Global Investment Conference
2022-05-12 11:00 ET
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
2022-05-05 11:00 ET
Aravive to Host Key Opinion Leader Symposium on May 11, 2022
2022-04-29 11:00 ET
Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting
2022-03-31 20:05 ET
Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
2022-03-30 12:00 ET
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2022-03-22 11:00 ET
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
2022-03-07 12:00 ET
Aravive to Participate In-Person at 34th Annual ROTH Conference
2022-03-03 12:00 ET
Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
2022-03-02 12:00 ET
Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting
2022-01-31 12:00 ET
Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
2022-01-03 23:15 ET
Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors
2021-11-15 12:00 ET
Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-12 12:00 ET
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma
2021-11-09 13:00 ET
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting
2021-10-28 20:01 ET
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
2021-10-01 12:00 ET
Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting
2021-09-16 11:00 ET
Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
2021-09-01 11:00 ET
Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-09 11:00 ET
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
2021-08-05 11:00 ET
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
2021-07-27 11:00 ET
Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
2021-07-15 11:00 ET
Aravive Achieves Second Development Milestone from 3D Medicines
2021-07-07 11:00 ET
Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
2021-06-24 11:00 ET
Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma
2021-05-18 11:00 ET
Aravive Announces Three New Appointments to its Board of Directors
2021-05-06 11:00 ET
Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer
2021-04-27 11:00 ET
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
2021-03-16 11:00 ET
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
2021-03-12 12:00 ET
Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting
2021-03-08 12:00 ET
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
2021-03-02 12:00 ET
Aravive to Participate in Upcoming Virtual Investor Conferences in March
2021-02-16 12:00 ET
Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market
2021-01-04 21:05 ET
Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
2021-01-01 00:00 ET
Aravive Announces Board Member Transition to Advisory Role
2020-11-19 12:00 ET
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
2020-11-16 21:05 ET
Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-10 21:05 ET
Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020
2020-11-10 12:00 ET
Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China
2020-11-05 21:05 ET
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
2020-09-17 11:00 ET
Aravive Appoints Michael W. Rogers to Board of Directors
2020-09-15 11:00 ET
Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer
2020-09-08 11:00 ET
Aravive to Participate in Upcoming Virtual Investor Conferences in September
2020-08-27 11:00 ET
Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans
2020-08-03 20:01 ET
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
2020-07-30 11:00 ET
Aravive to Participate in Upcoming Virtual Investor Conferences in August
2020-07-23 11:00 ET
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer
2020-06-30 20:05 ET
Aravive Added to the Russell 2000® and Russell 3000® Indexes
2020-05-12 12:00 ET
Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference
2020-05-06 20:05 ET
Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates
2020-04-30 12:00 ET
Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
2020-04-09 11:08 ET
Aravive Announces Board Composition and Executive Management Transitions
2020-03-30 12:00 ET
Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
2020-03-27 12:00 ET
Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates
2020-03-24 12:00 ET
Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
2020-02-25 21:07 ET
Aravive To Present at The Cowen and Company 40th Annual Health Care Conference
2020-02-18 13:00 ET
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
2020-01-13 13:00 ET
Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
2020-01-09 21:05 ET
Aravive Announces Management Changes
2019-12-20 13:00 ET
Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis
2019-12-02 13:00 ET
Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference
2019-11-27 13:30 ET
Aravive Announces Pricing of Public Offering of Common Stock
2019-11-26 22:14 ET
Aravive Announces Proposed Public Offering of Common Stock
2019-11-20 12:00 ET
Aravive Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer
2019-11-12 13:00 ET
Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
2019-11-07 21:05 ET
Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
2019-10-18 12:00 ET
Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research
2019-09-27 14:15 ET
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
2019-09-27 12:00 ET
Aravive Announces Participation at the 2019 Cantor Global Healthcare Conference
2019-09-18 12:00 ET
Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona

SEC forms

Show financial reports only

SEC form 10
2023-11-09 16:05 ET
Aravive reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Aravive published news for 2023 q3
SEC form 6
2023-08-24 17:18 ET
Aravive published news for 2023 q2
SEC form 10
2023-08-21 16:05 ET
Aravive reported for 2023 q2
SEC form 10
2023-08-21 00:00 ET
Aravive published news for 2023 q2
SEC form 6
2023-08-14 16:06 ET
Aravive published news for 2023 q2
SEC form 6
2023-08-02 16:18 ET
Aravive published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Aravive published news for 2023 q2
SEC form 10
2023-05-10 16:07 ET
Aravive published news for 2023 q1
SEC form 6
2023-05-10 16:05 ET
Aravive published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Aravive published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
Aravive published news for 2023 q1
SEC form 6
2023-04-11 07:10 ET
Aravive published news for 2023 q1
SEC form 6
2023-03-15 07:10 ET
Aravive published news for 2022 q4
SEC form 10
2023-03-15 07:05 ET
Aravive published news for 2022 q4
SEC form 8
2023-03-15 00:00 ET
Aravive reported for 2022 q4
SEC form 10
2023-03-15 00:00 ET
Aravive reported for 2022 q4
SEC form 8
2022-11-10 00:00 ET
Aravive reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Aravive reported for 2022 q3
SEC form 8
2022-08-11 00:00 ET
Aravive reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Aravive reported for 2022 q2
SEC form 10
2022-05-12 00:00 ET
Aravive reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Aravive reported for 2022 q1
SEC form 8
2022-03-31 00:00 ET
Aravive published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Aravive published news for 2021 q4
SEC form 8
2021-10-28 00:00 ET
Aravive published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Aravive published news for 2021 q3
SEC form 8
2021-08-05 00:00 ET
Aravive published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Aravive published news for 2021 q2
SEC form 10
2021-05-06 00:00 ET
Aravive published news for 2021 q1